
About this episode
In today's views
- Strategy | Nile Pharma (NIPH) is closing in on Rameda and this may trigger arbitrage opportunities
- ISPH | The decline in ISPH stock price yesterday confirms that 3Q25 results are strong.
- VALU | 9M25 bottom line is consistent with a full year target of EGP750 million
- ETEL | Share price is approaching our FV upper end of EGP73/share, what is incorporated and what’s not?
- MFPC | 3Q soft on volumes and FX, but gas policy shield supports premium
- EGCH | Resilient margins supported by pricing; operational recovery yet to show
- EKHO | 3Q25: On track for full-year guidance; 4Q25 poised for stronger finish
- LCSW | Economies of scale drive strong 3Q25; weak 4Q25 to derail EGP360m earnings target
- ORWE | Improved 3Q25 puts ORWE on track to meet revised 2025e guidance
Get every episode summarized
Each time Al Ahly Pharos publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Al Ahly Pharos

Technical Analysis 10 September 2026
Al Ahly Pharos
Sep 10, 20266:32skipped_language

Technical Analysis 9 September 2026
Al Ahly Pharos
Sep 9, 202610:00skipped_language

Technical Analysis 8 September 2026
Al Ahly Pharos
Sep 8, 20267:39pending

Technical Analysis 7 September 2026
Al Ahly Pharos
Sep 7, 202610:09skipped_language